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Results. During the course of follow-up [120 6 65 (SD)Significance of histologic patterns of glomerular injury upon
months], 60% of patients with category IV (diffuse proliferativelong-term prognosis in severe lupus glomerulonephritis.
glomerulonephritis) lesions entered a remission compared withBackground. Patients with systemic lupus erythematosus
have a spectrum of glomerular disease, but the different pat- only 38% of patients with category III ($50%, focal and seg-
terns of glomerular injury identified within the general category mental glomerulonephritis) lesions and 27% of patients with
of “severe” lupus glomerulonephritis are responsible for much category Vc ($50%) and Vd (P , 0.05). Renal survival at 10
of the morbidity and mortality in this disease. The glomerular years was 75% for those with category IV lesions, 47% for
injury patterns seen with severe lupus glomerulonephritis have patients with category Vc ($50%) and Vd, and 52% for pa-
been separated into distinct histopathologic groups to deter- tients with category III ($50%) lesions (P , 0.05). Based on
mine whether they can predict long-term patient outcome. multivariate analysis, patients with category III ($50%) or Vc
Methods. We analyzed the clinical follow-up of 85 patients ($50%) and Vd lesions had a relative risk of progression to
participating in a controlled prospective therapeutic trial for end-stage renal disease 2.9 times that of category IV patients
the treatment of severe lupus glomerulonephritis conducted (P , 0.01), while the likelihood of entering a remission was
from April 1981 to December 1988, with an average follow- 8.2 times greater for category IV patients (P 5 0.0001).
up of 10 years. Patients were classified according to the 1982 Conclusion. The histopathologic categorization among pa-World Health Organization classification for lupus glomerulo- tients with severe lupus glomerulonephritis provides informa-nephritis.
tion relevant to their long-term outcome.
1 The Lupus Nephritis Collaborative Study Group included the follow-
ing: E.J. Lewis, J.L. Roberts, M.M. Schwartz, R.A. Rodby, H.L. Corwin
The severity of the glomerular microvascular inflam-(Rush-Presbyterian St. Luke’s Medical Center, Chicago, IL); J.M.
Lachin, S-P. Lan, P. Cleary (George Washington University, Washing- mation seen in some patients with systemic lupus erythe-
ton, D.C.); J. Bernstein, H. Shapiro, B.F. Rosenberg (William Beau- matosus (SLE) is predictive of morbidity and mortalitymont Hospital, Royal Oak, MI); M.A. Pohl, J. Clough, G. Gephardt
in this disease [1–7]. The histopathology of severe lupus(Cleveland Clinic, Cleveland, OH); T. Berl (University of Colorado,
Denver, CO); N. Levin (Henry Ford Hospital, Detroit, MI); L.G. Hun- glomerulonephritis comprises distinct patterns of injury
sicker, S. Bonsib (University of Iowa, Iowa City, IA); N. Simon, H.
that were initially defined by the World Health Organiza-Friederici (Evanston Hospital, Evanston, IL); F. del Greco, F.A Carone
(deceased) (Northwestern University, Chicago, IL); L. Hebert, H.M. tion Classification of 1982 as focal and segmental glomer-
Sharma (Ohio State University, Columbus, OH); E. Nielson, J. Toma- ulonephritis (FSGN; category III), diffuse proliferative
zewski (University of Pennsylvania, Philadelphia, PA); A. Levey, A.
glomerulonephritis (DPGN; category IV), and complexUcci (Tufts-New England Medical Center, Boston, MA); J. Lehman,
S.S. Blumenthal, J. Garancis (Medical College of Wisconsin, Milwau- membranous glomerulonephritis (categories Vc, Vd) [8].
kee, WI); K. Shapiro, P. Chander (New York Medical College, Valhalla, Hence, there are definable morphological features thatNY); and F. Whittier, J.W. Graves, J. Bathon, R. Riley (West Virginia
determine the type of glomerular injury in any givenUniversity, Morgantown, WV). The Pathology Reading Committee
included the following: M.M. Schwartz (chairman; Rush-Presbyterian biopsy, thus allowing subclassification of the most severe
St. Luke’s Medical Center, Chicago, IL); J. Bernstein (William Beau- forms of lupus glomerulonephritis. Presumably this arraymont Hospital, Royal Oak, MI); G.H. Hill (Francis Scott Key Medical
of morphologic abnormalities represents distinctive dif-Institution, a Johns Hopkins Medical Institution, Baltimore, MD); K.
Holley (Mayo Clinic, Rochester, MN). ferences in the mediation of the immune response, which
leads to a specific type of glomerular inflammation. InKey words: lupus nephritis, proteinuria, remission, end-stage renal dis-
ease, pathology of lupus, morphology, lesions. 1995, the World Health Organizational committee rec-
ommended a change in categorization of FSGN (class
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Fig. 2. Diffuse proliferative glomerulonephritis. This glomerulus is rep-
resentative of the 15 glomeruli in the biopsy, and it shows diffuseFig. 1. Focal and segmental glomerulonephritis ($50%). This glomer-
endocapillary proliferation with occlusion of the capillaries, marginatedulus shows segmental necrosis involving 50% of the tuft with obliteration
neutrophils and monocytes, and karyorrhexis. Other glomeruli had wireof the capillaries, hypertrophy, and proliferation of the podocytes and
loops, hyaline thrombi, and crescents in five (hematoxylin and eosinscattered karyorrhectic debris. The uninvolved portions of the glomeru-
3475).lus has patent capillaries and mesangial proliferation. Twenty-eight of
30 glomeruli in this biopsy showed severe proliferative lesions, and
some had crescents; however, the glomerular pathology maintained a
segmental flavor (hematoxylin and eosin 3475).
rotic glomeruli, and the diagnosis of severe lupus glomer-
ulonephritis was based on the presence of proliferation
and/or necrosis in $50% of the glomeruli with or without
concomitant membranous glomerulonephritis [1]. Thissimilar behavior with respect to clinical course, it was
pathological rubric comprises three morphologically dis-recommended that biopsies classified as FSGN (category
crete forms of lupus glomerulonephritis: (1) FSGN withIII) with involvement of $50% of glomeruli be included
active and/or necrotizing lesions in 50% or more of glo-into the DPGN category (category IV). This report ex-
meruli (category III lesions $50%, 24 patients; Fig. 1)amined the long-term outcome of patients with severe
[8]; (2) DPGN in which there is inflammation in all orlupus glomerulonephritis to determine whether the cate-
nearly all (at least 80%) of the (nonhyalinized) glomeruligories originally described in the World Health Organi-
by severe cellular proliferation and infiltration in a globalzation Classification of 1982 [8] are not only distinctive
endocapillary, mesangiocapillary, or crescentic patternon the basis of morphology, but also have significant
or prominent extensive subendothelial deposits seen byimplications with respect to clinical course.
light or fluorescence microscopy (DPGN; category IV,
35 patients; Fig. 2) [8]; and (3) membranous glomerulo-
METHODS nephritis with superimposed severe focal and segmental
($50% glomerular involvement, category Vc, $50%;Patients
Fig. 3) or DPGN (category Vd; 26 patients total; Fig.Eighty-six patients with severe lupus glomerulone-
4). One patient was not classifiable. The activity indexphritis participated in the clinical trial conducted by the
(maximum score of 24 points) and chronicity index (max-
Collaborative Study Group from April 1981 to Decem- imum score of 12 points) were determined by The Pa-
ber 1988. We have now extended the mean follow-up to thology Reading Committee for each biopsy [12–14].
120 months. The entry criteria, therapeutic and medical Clinical, biochemical, and serologic information was
management protocols, and results of the initial study obtained on patients at baseline and at specified follow-
have been previously described [1, 10]. up times during the initial study. The study was termi-
The histologic diagnosis of severe lupus glomerulone- nated in March 1986, but patients were formally followed
phritis and the classification of the pathology according through December 1988 [1]. Clinical follow-up has now
to the 1982 WHO classification [8], as determined by The been extended to June 1998. Information on the current
Pathology Reading Committee of the Lupus Nephritis clinical status of the patients with respect to death, end-
Collaborative Study Group, was used in the present stage renal disease (ESRD), and biochemical results for
study. For purposes of correlation of morphologic fea- serum creatinine and urine protein was collected.
tures with clinical course, the diagnostic categorization
Laboratory analysiscarried out by The Pathology Reading Committee during
the course of the original trial was used for the current Baseline serum creatinine, C3 and C4 complement
components, anti–double-stranded DNA antibodies (anti-study [11]. An adequate biopsy contained .10 nonscle-
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Fig. 3. Membranous glomerulonephritis plus segmental proliferative Fig. 4. Membranous glomerulonephritis plus diffuse proliferative glo-
lesions in $50%. This glomerulus shows a segmental endocapillary merulonephritis. Lobulation and diffuse endocapillary proliferation
proliferative lesion (asterisk) with an adhesion to Bowman’s capsule. with widespread capillary occlusion can be seen. Similar lesions were
The remainder of the glomerulus has mesangial proliferation (moder- present in all 17 glomeruli in the biopsy. By fluorescence microscopy,
ately severe) and diffuse thickening of the capillary walls. Similar seg- there were diffuse granular deposits of IgG (hematoxylin and eosin,
mental lesions were present in 15 of 20 glomeruli in the biopsy. By 3475). The inset shows a representative segment of the glomerular
fluorescence microscopy, there were diffuse granular deposits of IgG capillary with subepithelial electron-dense deposits (uranyl acetate and
(hematoxylin and eosin, 3475). The inset shows a representative seg- lead citrate 318,000).
ment of the glomerular capillary wall with irregular subepithelial elec-
tron-dense deposits (uranyl acetate and lead citrate 315,000).
tional 12 treatments. Thereafter, renal and extrarenal
flares were treated based on other standardized protocolsdsDNA), C1q binding activity, and cryoglobulin concen-
of intensive drug therapy as previously described [10, 18].trations were determined in a central laboratory as pre-
After the formal study ended, the course of treatmentviously described [15]. A Creatinine Analyzer II (Beck-
was determined by the individual investigator.man Instruments, Fullerton, CA, USA) measured serum
creatinine with the use of a modified alkaline picrate Outcome variables
method. Serum C3 and C4 were measured by radial
The following outcomes were evaluated from the timeimmunodiffusion (Calbiochem-Behring, La Jolla, CA,
of entry into the study: (1) time to remission [definedUSA), and anti-dsDNA was measured by radioimmuno-
by a serum creatinine of #1.4 mg/dL (#123 mmol/L) andassay (Amersham, Arlington Heights, IL, USA). Anti-
proteinuria of #0.33 g/day] within five years of enteringbodies to Ro, La, nRNP, and Sm were determined by a
study, (2) time to end-stage renal disease [defined by asingle investigator (M.R.) using an enzyme-linked immu-
serum creatinine of $6 mg/dL ($528 mmol/L), or thenosorbent assay (ELISA) with affinity-purified antigens
initiation of renal replacement therapy], and (3) death.as previously described [16, 17].
An assessment of renal function was made at four
Treatment protocol weeks. Worsening of renal function was defined by an
increase in serum creatinine of $0.3 mg/dL ($26 mmol/L)The details of the treatment protocols for this study
if the patient’s initial serum creatinine was ,2.0 mg/dL, anhave been published [1, 10, 18]. All patients initially
increase in serum creatinine of $0.4 mg/dL ($35 mmol/L)received 60 mg of prednisone per day orally and 2 mg/kg
if the patient’s initial serum creatinine was 2.0 to ,5 mg/dL,per day of cyclophosphamide orally. Forty patients were
an increase in serum creatinine of $0.5 mg/dL ($44randomized to receive standard therapy plus plasma-
mmol/L) if the patient’s initial serum creatinine was $5.0pheresis three times weekly for four weeks in addition to
mg/dL, or doubling of urinary protein to twice baseline.this treatment. After the initial four weeks of treatment,
Patients not meeting these criteria were otherwise con-patients who improved clinically received cyclophospha-
sidered as stable.mide at 1 mg/kg/day for an additional month, after which
Lupus flares were defined as follows: (1) mild renalit was discontinued. The dose of prednisone was gradu-
flare, reappearance of active urine sediment (red bloodally tapered over a 22-week period to 20 mg on alternate
cell casts); (2) moderate renal flare, a sudden increasedays. Patients whose renal symptoms had worsened at
in serum creatinine of .0.3 mg/dL (. 26 mmol/L) or anfour weeks (discussed later in this article) were continued
increase in proteinuria of .1.0 g/day; and (3) severeon the initial high-dose prednisone and cyclophospha-
renal flare, a sudden increase in serum creatinine of .1mide for an additional four weeks, and patients in the
plasmapheresis arm of the study also received an addi- mg/dL (.88 mmol/L) [1, 10].
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Table 1. Baseline clinical characteristics
Vc ($50%)
Categories All III ($50%) IV and Vd
N 86 24 35 26
Age years 32612 36616 2968 31613
Female 72 (84%) 19 (79%) 30 (86%) 22 (85%)
Race
White 54 (63%) 15 (63%) 23 (66%) 15 (58%)
Black 21 (24%) 7 (29%) 5 (14%) 9 (35%)
Other 11 (13%) 2 (8%) 7 (20%) 2 (8%)
BP mm Hg
Systolic 142619 140621 142614 144623
Diastolic 88612 85612 91611 88614
SCr mg/dL 1.961.2 1.661.0 1.861.1 2.161.5
Median 1.5 1.4 1.5 1.8
UProtein g/day 5.964 4.462.9 6.364.1 6.864.3
Median 5.5 3.9 6.6 6.1
Presentation-entry months 16633a 467 16640 25635
Median 1.2 1.1 0.7 5.7
Biopsy-entry months 0.460.6 0.460.6 0.460.4 0.560.6
Median 0.20 0.20 0.20 0.25
Values reported as number or mean 6 SD. Abbreviations are: BP, blood pressure; SCr, serum creatinine; UProtein, urine protein.
a P 5 0.02, IV vs. Vc ($50%) and Vd
Table 2. Baseline serologyStatistical analysis
Vc ($50%)Comparison of the clinical and laboratory characteris-
Categories All III ($50%) IV and Vdtics among the groups of patients used the Fisher’s exact
N 86 24 35 26test for categorical data [19] and the Kruskal–Wallis non-
dsDNA mU/L 2896541 2816350 3936750 1666233
parametric analysis of variance test and the Wilcoxon .20 mU/L 83 (97%) 22 (92%) 34 (97%) 26 (100%)
C3 mg/dL 40617 46619 34614 42618rank-sum test for continuous data [20]. For the analysis
,80 mg/dL 84 (98%) 23 (96%) 35 (100%) 25 (96%)of length of time from entry to ESRD (renal survival) C4 mg/dL 15612 18613 1269 16612
or death (patient survival), product-limit life-table distri- ,15 mg/dL 54 (63%) 14 (58%) 24 (67%) 14 (54%)
Cryo lg/mL 168663 131699 2296385 1246124butions were compared with the log-rank test statistic
.21 lg/mL 79 (92%) 22 (92%) 31 (89%) 25 (96%)
[21]. A proportional hazards regression model was used N 80 22 31 26
Anti-Ro 27 (34%) 6 (27%) 10 (32%) 10 (38%)to evaluate potential baseline clinical (age, race, sex,
Anti-LA 6 (8%) 2 (9%) 3 (10%) 1 (4%)blood pressure, time from renal presentation to study Anti-nRNP 35 (48%) 8 (36%) 16 (52%) 11 (42%)
entry), laboratory (serum creatinine, 24-hour urine pro- Anti-Sm 29 (36%) 7 (32%) 11 (35%) 11 (42%)
tein), serologic (dsDNA, C3, C4, cryoglobulin, anti-Ro, Values are reported as number or mean 6 SD. Abbreviations are: dsDNA,
double-strand DNA antibodies; C3 and C4, complement components; Cryo,anti-La, anti-nRNP, and anti-Sm levels), histologic (his-
cryoglobulin level.
tologic category, activity, and chronicity indices), and
therapeutic (initial treatment, status at 4 weeks, renal
flares) predictors of progression to ESRD, and remission
Histopathology[21]. Results are reported as mean 6 SD, and a P value
Significant differences in histologic features among the,0.05 was considered significant.
three lesions included the observation that biopsies with
severe FSGN (category III $50%) had a greater percent-
age of glomeruli with segmental endocapillary prolifera-RESULTS
tion (P , 0.01), segmental fibrin deposition (P , 0.01),Baseline clinical and serological characteristics
and hematoxyphil bodies (P , 0.05; Table 3). Active
While the duration of glomerulonephritis prior to segmental lesions were found in 75 6 13% of viable
study entry was significantly longer for patients with com- glomeruli in biopsies with severe FSGN (category III
plex membranous glomerulonephritis [categories Vc $50%).
($50%) and Vd], the demographic, clinical, and sero- Biopsies with category IV lesions demonstrated a sig-
logic characteristics at entry into the study were similar nificantly greater proportion of glomeruli with wire loops
among the three groups (Tables 1 and 2). There was (P , 0.01, P , 0.05) and hyaline thrombi (P , 0.05,
no significant difference in therapeutic randomization P , 0.01) on light microscopy, and accordingly, the per-
centage of glomeruli with massive subendothelial depos-during the formal trial among the three groups.
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Table 3. Glomerular pathology likely to enter a remission than patients with category
III ($50%) or category Vc ($50%) and Vd lesions. TheVc (.50%)
Categories III ($50%) IV and Vd cumulative remission rate by five years was 73% for
N 24 35 26 patients with category IV lesions, 48% for patients with
Glomeruli/biopsy 1867 19 610 21612 category III ($50%) lesions, and 41% for patients withActive lesionsa
SEC proliferationb 37630% 16621% 22620% category Vc ($50%) and Vd lesions (Fig. 5). Renal
Cell wall disruption 366% 5612% 264% flares, moderate and severe, were equally common
Karyorrhexis 24619% 26628% 20617%
among patients in all three categories (Table 4).Hematoxyphil bodiesc 10614% 569% 468%
Crescents 18630% 17621% 13615% At last follow-up, patients with category IV lesions
Wire-loopsd 14621% 41635% 1763% were more likely to have stable renal function and lessHyaline thrombie 469% 14617% 265%
Massive SE depositsf 9615% 34627% 20624% likely to progress to ESRD or death (renal and nonrenal)
Fibrin thrombi 0.662.5% 0.261.3% 1.964.7% than those with category III ($50%) or Vc ($50%) and
Segmental fibring 568% 3611% 265%
Vd lesions (Table 4).Scarring lesionsa
Hyalinized glomeruli 12615% 8615% 13613%
Segmental scars 9615% 469% 963% Survival outcomes
Mesangial cellularity N 23 34 25
Normal/mild 15 4 17 Renal survival at 5 and 10 years was significantly better
Moderate/severeh 8 30 8 in patients with category IV lupus glomerulonephritisGlomerulosclerosisi N 23 34 25
compared with patients with category III ($50%) or0–25% 23 32 20
.25% 0 2 5 category Vc ($50%) and Vd lesions (Table 5 and Fig.
Tubular atrophy N 22 34 25
6). The renal survival for patients within the category of0–25% 17 28 17
.25% 5 6 8 complex membranous glomerulonephritis [Vc ($50%)
Interstitial fibrosis N 22 34 25 and Vd] was evaluated further, based on the nature of0–25% 18 27 17
the acute inflammatory lesion. The renal survival for.25% 4 7 8
Activity index 11.263.8 13.165.3 11.563.7 patients with category Vc ($50%) lesions was similar to
$12 10 (42%) 20 (57%) 12 (46%)
that of patients with category III ($50%) lesions, andChronicity index 3.862.6 2.662.5 4.062.0
$4 11 (46%) 14 (40%) 15 (58%) those patients with category Vd lesions had a renal sur-
Data are mean 6 SD. Abbreviations are: SEC, segmental endocapillary prolif- vival similar to patients with category IV lesions (Table
eration; SE, subendothelial deposits. 5 and Fig. 6). Among patients with focal and segmentala Percent of glomeruli with the feature
b P , 0.01, III ($50%) vs. IV forms of lupus glomerulonephritis [category III ($50%)
c P , 0.05, III ($50%) vs. Vc ($50%) and Vd
and Vc ($50%)], the absolute percentage of glomerulid P , 0.01, IV vs. III ($50%); P , 0.05, IV vs. Vc ($50%) and Vd
e P , 0.05, IV vs. III ($50%); P , 0.01, IV vs. Vc ($50%) and Vd with active lesions did not translate into differences forf P , 0.001, IV vs. III ($50%)
g P , 0.01, III ($50%) vs. IV patient or renal survival (data not shown). There were
h P , 0.0001, IV vs. III ($50%); P , 0.0001, IV vs. Vc ($50%) and Vd no significant differences in patient survival among thei P 5 0.05, III ($50%) vs. Vc ($50%) and Vd
three groups (Table 5).
Multivariate analysis
its by electron microscopy was significantly higher (P , The histopathologic category was predictive of renal
0.001) in biopsies with category IV lesions. The presence
outcome in severe lupus glomerulonephritis. Patients
of severe mesangial hypercellularity was also greatest in
with category IV lesions were 8.2 times more likely topatients with DPGN than patients with either category
enter a remission compared with those with category IIIIII ($50%, P , 0.0001) or category Vc ($50%) and Vd
($50%) or Vc ($50%) and Vd lesions (P 5 0.0001).lesions (P , 0.0001). Finally, indices of histologic activity
An evaluation of predictors of ESRD found that patientsand chronicity suggested more active glomerular disease
with category III ($50%, FSGN) or category Vc ($50%,(increased activity index) and less chronic histologic
membranous glomerulonephritis with FSGN) and cate-damage (lower chronicity index) in biopsies with DPGN
gory Vd (membranous glomerulonephritis with DPGN)than in patients with the other lesions.
lupus glomerulonephritis were 2.9 times more likely to
Follow-up progress to ESRD than patients with category IV (DPGN)
lupus glomerulonephritis (Table 6). In addition, the ini-The duration of follow-up was similar in all three
tial serum creatinine and the presence of anti-Ro anti-groups (Table 4). The percentage of patients with stable
bodies were also predictive of ESRD. However, patientsrenal function after four weeks of therapy was highest
who attained a remission were significantly less likely toamong patients with categories IV and III ($50%) le-
sions. Patients with DPGN (category IV) were more progress to ESRD (relative risk 5 0.12, P , 0.001).
Najafi et al: Patterns of glomerular injury in SLE 2161
Table 4. Follow-up
Categories All III ($50%) IV Vc ($50%) and Vd
N 86 24 35 26
Follow-up months 120665 124661 126664 108670
Renal status at week 4
Stable 74 (86%) 22 (92%) 31 (89%) 20 (77%)
Worse 12 (14%) 2 (8%) 4 (11%) 6 (23%)
Remissiona 37 (43%) 9 (38%) 21 (60%) 7 (27%)
No remission 49 (57%) 15 (63%) 14 (40%) 19 (73%)
Renal flares N
Total 46 (53%) 15 (62%) 19 (54%) 12 (46%)
Moderate/severe 43 (50%) 14 (46%) 17 (49%) 11 (42%)
Status at last follow-up
Stable renal functionb 40 (48%) 9 (38%) 22 (63%) 9 (35%)
End point (ESRD/death) 46 (52%) 15 (62%) 13 (37%) 17 (65%)
ESRD 22 (24%) 9 (38%) 5 (14%) 8 (31%)
Renal death 15 (17%) 4 (17%) 4 (11%) 6 (23%)
Nonrenal death 9 (10%) 2 (8%) 4 (11%) 3 (12%)
Values reported as number or mean 6 SD. Abbreviations are: ESRD, end-stage renal disease; NR, nonrenal.
a P , 0.02, IV vs. Vc ($50%) and Vd
b P 5 0.06, IV vs. III ($50%); P , 0.05, IV vs. Vc ($50%) and Vd
Fig. 5. Proportion of patients entering remission based on histologic Fig. 6. Renal survival based on histologic categorization and subcateg-
category (censoring for ESRD and death). Category III ($50%) (N 5 orization (censoring for nonrenal death). Category III ($50%) (N 5 24),
24), category IV (N 5 35), and category Vc $50% and Vd (N 5 26). category IV (N 5 35), and category Vc ($50%) (N 5 20) and Vd (N 5 6).
P , 0.05, overall; P , 0.05, IV vs. III ($50%); P , 0.05, IV vs. Vc P 5 0.01, overall; P 5 0.05, IV vs. III ($50%); P 5 0.002, IV vs. Vc
($50%) and Vd. ($50%).
Table 5. Patient and renal survival
Category All III ($50%) IV Vc (.50%) Vd Vc ($50%) and Vd
Renal survivala
5 years 68% 66% 79% 52% 75% 57%
10 years 59% 52% 75% 40% 75% 47%
15 years 50% 43% 71% 16% 75% 31%
Patient survival
5 years 80% 83% 83% 74% 67% 73%
10 years 75% 78% 80% 68% 67% 68%
15 years 70% 78% 73% 61% 67% 63%
aP , 0.05, overall; P 5 0.05, IV vs. III ($50%); P 5 0.01, IV vs. Vc ($50%) and Vd; P 5 0.002, IV vs. Vc ($50%)
DISCUSSION in response to therapy and renal survival among the
histologic categories that define severe lupus glomerulo-Patients with severe glomerulonephritis constitute a
nephritis articulated in the World Health Organizationpopulation of patients with SLE at risk not only for pro-
classification of 1982 [8]. This classification was utilizedgressive renal dysfunction, but also increased mortality
[11, 22–24]. Our study demonstrates important differences because it recognizes valid qualitative morphological dif-
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Table 6. Multivariate analysis for predictors of loops, and hyaline thrombi. In contrast, segmental endo-
end-stage renal diseasea
capillary proliferation and segmental fibrin deposition
Variable Relative risk 95% CI P value characterized the lesion of severe segmental glomerulo-
Serum creatinineb 3.0 2.1–4.3 0.0001 nephritis [category III ($50%)]. Subendothelial deposits
Anti-Ro present 2.2 1.1–4.4 ,0.05 were not a dominant feature in biopsies in category III
No category IV lesion 2.9 1.4–6.5 ,0.01
($50%). An intense segmental inflammatory lesion with
CI is confidence interval karyorrhexis, cell wall destruction, and crescents was fre-a Remission status not included in analysis
b Relative risk per increase of 1 mg/dL quently seen in category III ($50%) biopsies. The relative
absence of extensive subendothelial immune-aggregates
in category III ($50%) suggests that the immunopatho-
genesis of the segmental lesion may be different from
ferences between the segmental lesions found in FSGN that seen in the global acute inflammatory response of
(category III) and the global changes of DPGN (category DPGN. Conceivably, the biological properties of depos-
IV). Our results support the continued recognition of ited antibody or the involvement of cellular hypersensi-
these distinct categories as the specific histologic features tivity may explain these observations [28–30]. SLE pa-
of independent categories translate into different short- tients with focal and segmental glomerular inflammation
and long-term clinical outcomes. Patients with diffuse and necrosis lacking immune deposits, similar to the le-
proliferative glomerulonephritis (category IV) were more sions of systemic vasculitis, have been described, suggest-
likely to enter a remission compared with patients with ing a role for cellular hypersensitivity in the immunopatho-
severe focal and segmental glomerulonephritis [category logical process [31–34]. On the basis of our observations,
III ($50%)] or membranous glomerulonephritis with the recommendation that category III and category IV
superimposed proliferation [category Vc ($50%) and biopsies represent a continuum that ultimately results in
Vd], indicating a superior response to therapy. Category the global inflammation of diffuse glomerulonephritis
IV patients fared better with respect to long-term renal appears to be an oversimplification that ignores both the
survival, supporting previously reported evidence that characteristic morphologic features of each lesion and
clinical renal remission predicts a more favorable prog- the clinical course and response to therapy. Patients with
nosis among patients with lupus glomerulonephritis severe segmental glomerulonephritis have a poorer
[18, 25]. The presence of category III ($50%) or Vc prognosis than patients with diffuse proliferative glomer-
($50%) and Vd lesion was predictive of progression to ulonephritis and warrant being separated if only to ac-
end-stage renal disease. While a wealth of literature [3, knowledge this difference.
4, 8, 23, 24, 26, 27] highlights the relatively malignant Renal survival in patients with membranous glomeru-
nature of diffuse proliferative glomerulonephritis (cate- lonephritis and superimposed severe segmental glomeru-
gory IV), our results reveal that severe focal and segmen- lonephritis [category Vc ($50%)] was similar to patients
tal glomerulonephritis [category III ($50%)] and com- with severe focal and segmental glomerulonephritis [cat-
plex membranous [category Vc ($50%) and Vd] forms egory III ($50%)]. Likewise, patients with membranous
of lupus glomerulonephritis are associated with even and superimposed diffuse glomerulonephritis (category
poorer clinical prognoses. Vd) followed a course similar to patients with diffuse
It has been recommended recently that patients with glomerulonephritis (category IV), suggesting that the
focal and segmental lupus glomerulonephritis involving mechanisms behind the pattern of inflammation and pro-
$50% of the glomeruli be combined within the category liferation dictated the outcome.
of diffuse proliferative glomerulonephritis (category IV) In conclusion, histopathologic categorization among
[9]. The assertion has been made that these patients [with patients with severe lupus glomerulonephritis does pro-
category III ($50%)] follow a clinical course similar vide information relevant to their long-term outcome.
to patients with diffuse proliferative glomerulonephritis Including all patients with proliferative forms of glomer-
(category IV) and therefore warrant classification as ulonephritis into a single category of diffuse glomerulo-
such. The literature has not conclusively supported this nephritis ignores morphologically distinct patterns that
assertion [7, 11, 27]. Our results indicate that the immune correlate with critical clinical differences with regard to
inflammatory patterns associated with the segmental le- attainment of remission and long-term renal survival
sions of category III ($50%) and category Vc ($50%) among patients with the most severe forms of lupus glo-
are distinct morphologically. Other significant differences merulonephritis. Treatment strategies for patients with
in the morphologic features of the glomerular lesion were severe segmental forms of lupus glomerulonephritis, in-
observed. Patients with diffuse proliferative glomerulo- cluding those patients with a membranous component,
nephritis (category IV) had more evidence for immune- may require alteration in order to address the possible
aggregate deposition, with the greatest proportion of role of immune mechanisms similar to that of the pauci-
immune lesion of the systemic vasculitides. The degreeglomeruli having massive subendothelial deposits, wire
Najafi et al: Patterns of glomerular injury in SLE 2163
indices in the management of severe lupus glomerulonephritis.and duration of therapy in patients whose biopsies reveal
Kidney Int 42:743–748, 1992
severe focal and segmental glomerulonephritis [category 15. Roberts JL, Lewis EJ: Identification of antinative DNA antibodies
in cryoglobulinemic states. Am J Med 65:437–455, 1978III ($50%)] may have to be more aggressive than thera-
16. Harley JB, Sestak AL, Willis LG, et al: A model for diseasepeutic protocols applied to those with diffuse prolifera-
heterogeneity in systemic lupus erythematosus. Arthritis Rheum
tive glomerulonephritis (category IV). The accurate 32:826–836, 1989
17. Reichlin M: Measurements of antibodies to Sm and nRNP bypathological stratification of renal biopsies is essential to
ELISA: Clinical and serological correlations, in Mixed Connectivethe ultimate definition of the optimal therapy for patients
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